Tous Actualités
Suivre
Abonner Corus Pharma

Corus Pharma

Aztreonam Data to Be Presented at European Cystic Fibrosis Society Conference

Seattle (ots/PRNewswire)

- Data on Microbiology of an Investigational Inhaled Antibiotic
for  Cystic Fibrosis to Be Presented in Crete
Dr. Jane L. Burns will present Corus Pharma's Aztreonam Lysinate
for  Inhalation (AI) clinical Phase 2 microbiology results at the
European Cystic  Fibrosis Society Conference (ECFS) in Crete on
Friday, June 24, 2005 at 5:00  p.m. EEST (Eastern European Summer
Time) as part of a session on antibiotics  and resistance.
     WHO:      Dr. Jane L. Burns and Corus Pharma
     WHAT:     Presentation of Corus Pharma's Aztreonam Lysinate for
               Inhalation (AI) clinical Phase 2 microbiology results.
     WHEN:     Friday, June 24, 2005 at 5:00 p.m.
     WHERE:    Creta Maris, Crete (Athena room)
About The Phase 2 Results
The Phase 2 study was comprised of 105 cystic fibrosis (CF)
patients with pulmonary Pseudomonas aeruginosa infections. It
evaluated two dose groups (75 mg and 225 mg) with twice daily
applications for two weeks in a double blinded, placebo-controlled
trial.
Both dose levels were well tolerated with similar adverse event
profiles as the placebo, though the 225 mg dose had a trend to
increased respiratory symptoms (most commonly cough) when compared to
either the 75 mg dose or placebo. There were no serious adverse
events reported as related to AI.
There was a significant decrease in the amount of Pseudomonas
aeruginosa as measured by sputum density with both dose groups
showing greater than or equal to 97% reduction (greater than or equal
to 1.5 log) from baseline (p < 0.001). In patients with abnormal lung
function at baseline, there was a significant improvement in FEV1
measured over the duration of the study (p < 0.05).
Based on the Phase 2 results, Corus is currently enrolling
patients in the AIR-CF Phase 3 clinical trials and more information
can be found at www.AIR-CF.com. AI is delivered by the eFlow(R)
Electronic Nebulizer developed by PARI GmbH with an average treatment
time in Corus' Phase 2 clinical trial of 2.4 minutes for the 75mg
dose.
About Dr. Jane L. Burns
Jane L. Burns, MD, is a Professor of Pediatrics at the University
of Washington in Seattle, Washington. She is also Director of the
Cystic Fibrosis Microbiology Laboratory and the Infectious Disease
Clinic at Children's Hospital and Regional Medical Center, also in
Seattle. Dr. Burns earned her medical degree from the University of
Washington.
About Corus Pharma
Corus Pharma is committed to developing and commercializing
products for severe respiratory and infectious diseases that can help
provide improved health and quality of life. More information about
Corus Pharma may be found at www.coruspharma.com.
Web site: http://www.coruspharma.com

Contact:

Jonathan Mow of Corus Pharma, +1-206-792-3020, or
jmow@coruspharma.com; or Leslie Cohan of Dave Syferd & Partners,
+1-206-262-0395, or cell, +1-206-849-1810, or lcohan@dsandp.com, for
Corus Pharma